tetano
Editor, Senior Moderator
Rheumatol Int
. 2021 Jun 5.
doi: 10.1007/s00296-021-04902-7. Online ahead of print.
COVID-19 in patients with gout on colchicine
Eleftherios Pelechas[SUP] 1 [/SUP], Vassiliki Drossou[SUP] 1 [/SUP], Paraskevi V Voulgari[SUP] 1 [/SUP], Alexandros A Drosos[SUP] 2 [/SUP]
Affiliations
Abstract
Current data demonstrated that severe cases of coronavirus-disease-19 (COVID-19) require treatment with antiviral therapy, dexamethasone, supportive care, as well as some anti-rheumatic drugs, among them, cytokine inhibitors and colchicine. Colchicine is an anti-inflammatory drug that is being used in rheumatology for many years to treat mostly gout, calcium pyrophosphate deposition disease, and Familial Mediterranean Fever. Here, we present for the first time, two patients suffering from gout being treated with colchicine, who were affected from severe acute respiratory coronavirus-2 (SARS-CoV-2) syndrome. Both patients presented with mild symptoms of COVID-19 expressed with myalgias, arthralgias, and sore throat, while laboratory investigations showed only high acute phase reactants. Four weeks later, both patients were free of symptoms with negative SARS-CoV-2 tests and without any complications. To our knowledge, there are no other studies of gout arthritis and SARS-CoV-2 infection published so far. Thus, our preliminary conclusion is that chronic use of colchicine may mitigate the clinical picture and disease course of COVID-19 in gout arthritis patients. Further studies with a large number of patients are needed to confirm the above beneficial effect of colchicine.
Keywords: COVID-19; Colchicine; Cytokine inhibitors; Gout arthritis; Inflammasome; Systemic inflammation.
. 2021 Jun 5.
doi: 10.1007/s00296-021-04902-7. Online ahead of print.
COVID-19 in patients with gout on colchicine
Eleftherios Pelechas[SUP] 1 [/SUP], Vassiliki Drossou[SUP] 1 [/SUP], Paraskevi V Voulgari[SUP] 1 [/SUP], Alexandros A Drosos[SUP] 2 [/SUP]
Affiliations
- PMID: 34089357
- DOI: 10.1007/s00296-021-04902-7
Abstract
Current data demonstrated that severe cases of coronavirus-disease-19 (COVID-19) require treatment with antiviral therapy, dexamethasone, supportive care, as well as some anti-rheumatic drugs, among them, cytokine inhibitors and colchicine. Colchicine is an anti-inflammatory drug that is being used in rheumatology for many years to treat mostly gout, calcium pyrophosphate deposition disease, and Familial Mediterranean Fever. Here, we present for the first time, two patients suffering from gout being treated with colchicine, who were affected from severe acute respiratory coronavirus-2 (SARS-CoV-2) syndrome. Both patients presented with mild symptoms of COVID-19 expressed with myalgias, arthralgias, and sore throat, while laboratory investigations showed only high acute phase reactants. Four weeks later, both patients were free of symptoms with negative SARS-CoV-2 tests and without any complications. To our knowledge, there are no other studies of gout arthritis and SARS-CoV-2 infection published so far. Thus, our preliminary conclusion is that chronic use of colchicine may mitigate the clinical picture and disease course of COVID-19 in gout arthritis patients. Further studies with a large number of patients are needed to confirm the above beneficial effect of colchicine.
Keywords: COVID-19; Colchicine; Cytokine inhibitors; Gout arthritis; Inflammasome; Systemic inflammation.